Get access

Oromandibular dystonia: Long-term management with botulinum toxin

Authors

  • Catherine F. Sinclair MD,

    1. New York Center for Voice and Swallowing Disorders, St. Luke's Roosevelt Medical Center, New York, New York, U.S.A.
    Search for more papers by this author
  • Lowell E. Gurey MD,

    1. New York Center for Voice and Swallowing Disorders, St. Luke's Roosevelt Medical Center, New York, New York, U.S.A.
    Search for more papers by this author
  • Andrew Blitzer MD, DDS

    Corresponding author
    1. New York Center for Voice and Swallowing Disorders, St. Luke's Roosevelt Medical Center, New York, New York, U.S.A.
    • Send correspondence to Andrew Blitzer, MD, New York Center for Voice and Swallowing Disorders, St. Luke's Roosevelt Medical Center, 425 West 59th Street, 10th Floor, New York, NY 10019. E-mail: ab1136@aol.com

    Search for more papers by this author

  • Delivered as an oral presentation at the Triological Society Combined Sections Meeting, Miami, Florida, U.S.A., January 26–28, 2012.

  • Dr. Blitzer has received funding from and is a consultant for Allergan, Inc., Merz Pharmaceuticals, and Revance. The authors have no other funding, financial relationships, or conflicts of interest to disclose.

Abstract

Objectives/Hypothesis

To review the long-term management of patients with oromandibular dystonia (OMD) treated using botulinum toxin.

Study Design

Retrospective chart review at a clinical research center.

Methods

Between 1995 and 2011, 59 patients with a diagnosis of OMD were treated with botulinum toxin. Data were collected on patient demographics, disease characteristics, and long-term treatment outcomes. Differences in management between an earlier published series of the first 20 OMD patients treated with botulinum toxin at this center and subsequent patients were analyzed.

Results

Patients were more commonly female (72% vs. 28%) with an average age at first botulinum treatment of 56.6 years. The median number of treatments was five (range, 1–35 treatments). Average time between treatments was 3.8 months (±5.2). Overall, 47.5%, had the jaw-closing form of OMD, which was associated with a preferential deviation to one side in 53.6%. These patients received initial injections to the masseter ± temporalis muscle; the external pterygoid was injected for associated lateral jaw deviation. Internal pterygoid injections were rarely used (3.4%). For the jaw-opening form, injections were initially administered to the external pterygoid, with the addition of anterior digastric for ongoing symptoms. When compared with patients in the older series, more patients since 1988 had treatments to the external pterygoid (P = .001) and anterior digastric (P = .006) in accordance with an increase in the diagnosis of jaw-opening OMD (P = .05).

Conclusions

Long-term management of OMD with botulinum toxin has minimal morbidity and is useful for all clinical forms. Injections can be titrated by dose and location to address the predominant muscle groups involved.

Level of Evidence: 4 Laryngoscope, 123:3078–3083, 2013

Get access to the full text of this article

Ancillary